NextCure (NASDAQ:NXTC) Receives New Coverage from Analysts at Bank of America
Bank of America started coverage on shares of NextCure (NASDAQ:NXTC) in a research note released on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $25.00 target price on the stock.
A number of other analysts have also commented on NXTC. Piper Jaffray Companies lowered shares of Cypress Semiconductor from an overweight rating to a neutral rating in a research note on Monday, June 3rd. Morgan Stanley lowered shares of Meili from an equal weight rating to an underweight rating and reduced their price target for the stock from $14.00 to $4.20 in a research note on Monday, June 3rd.
Shares of NXTC stock opened at $17.01 on Tuesday. The business has a 50 day moving average of $16.62. NextCure has a 52 week low of $13.86 and a 52 week high of $22.75.
In other NextCure news, Director Stella Xu bought 125,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $1,875,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder X L.P. Canaan bought 50,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average price of $15.00 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here.
NextCure Company Profile
There is no company description available for NextCure Inc
Read More: Insider Trading – What You Need to Know
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.